Biologic therapy and psoriasis;Terapia biológica y psoriasis

Actas Dermo-Sifiliograficas

Volumn 97, Issue 1, 2006, Pages 1-17

  Gamo, Reyes ^a   López Estebaranz, José L ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Alefacept; Biologic therapy; Efalizumab; Etanercept; Infliximab; Psoriasis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; BASILIXIMAB; CYTOKINE; DACLIZUMAB; EFALIZUMAB; ETANERCEPT; IBUPROFEN; IDEC 114; INFLIXIMAB; MONOCLONAL ANTIBODY; ONERCEPT; PARACETAMOL; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 4; SIPLIZUMAB; UNCLASSIFIED DRUG;

ABSCESS; ANGIONEUROTIC EDEMA; ANTIGEN PRESENTING CELL; ARTHRALGIA; ASTHENIA; BIOLOGICAL THERAPY; CELL ACTIVATION; CELLULITIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; EDEMA; ERYTHEMA; FEVER; HEADACHE; HEMATOMA; HUMAN; IMMUNE RESPONSE; INFECTION; LIVER TOXICITY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; MYALGIA; NAUSEA; NEOPLASM; NEPHROTOXICITY; PAIN; PATHOGENESIS; PHARYNGITIS; PNEUMONIA; PRURITUS; PSORIASIS; QUALITY OF LIFE; RASH; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SINUSITIS; SKIN INFLAMMATION; SKIN TUMOR; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TREATMENT FAILURE; TUBERCULOSIS; URTICARIA;

EID: 33645029001     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(06)73342-7     Document Type: Review

References (60)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment Dermatol Clin. 1996;14:485-96.
2. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life. Arch Dermatol. 2001;137:280-4.
3. Weiss SC, Kimbalt AB, Liewehr DJ, et al. Quantifying the harmful effect of psoriasis on health related quality of life. J Am Acad Dermatol. 2002;47:512-8.
4. Sterry W, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis; International Consensus Conference. Br J Dermatol. 2004;151:3-17.
5. Schleyer V, Landthaler M, Szeimies RM. Novel pharmacological approaches in the treatment of psoriasis. JEADV. 2005;19:1-20.
6. Barry J, Kirby B. Novel biologic therapies for psoriasis. Expert Opin Biol. 2004;4:975-87.
7. Kanikatis J, Butnaru AC, Claudy A. Novel biological inmunotherapies for psoriasis. Exp Opin Investig Drugs. 2003;12:1111-21.
8. Villadsen LS, Skov L, Baadsgaard O. Biological response modifiers and their potential use in the treatment of inflammatory skin diseases. Exp Dermatol. 2003;12:1-10.
9. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113:1664-75.
10. Gottlieb A. Novel immunotherapies for Psoriasis: Clinical Research delivers new hope for patients and scientific advances. J Investig Dermatol Symp Proc. 2004;9:79-83.
11. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis. Arch Dermatol. 2002;138:657-63.
12. Peñas PF, Jones-Caballero M. Anticuerpos monoclonales en el tratamiento de la psoriasis. Actas Dermosifiliogr. 2002;93:355-63.
13. Walsh SR, Shear NH. Psoriasis and the new biologic agents: interrupting the T-AP dance. CMAJ. 2004;170:1933-41.
14. Lebwohl M. Innovations in the treatment of psoriasis. J Am Acad Dermatol. 2004;51:40-1.
15. Sobell JM, Hallas SJ. Systemic therapies for psoriasis: understanding current and newly emerging therapies. Semin Cutan Med Surg. 2003;22:187-95.
16. Da Silva AJ, Brickelmaier M, Majeu GR, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induce CD16 signalling and CD2/CD16-dependent apoptosis of CD2+ T-cells. J Immunol. 2002;168:4462-71.
17. Hussar DA. New drugs of 2003. J Am Pharm Assoc. 2004;44:168-210.
18. Tutrone W, Saini R, Weinberg JM. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept. Drugs. 2004;7:45-9.
19. Ellis CN, Krueger GG. Treatment of crohnic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345:248-55.
20. Lebwohl M, Cristophers E, Langley R, et al. An international, randomized, double bind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with crohnic plaque psoriasis. Arch Dermatol. 2003;139:719-27.
21. Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with crohnic plaque psoriasis. Br J Dermatol. 2003;148:784-8.
22. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-bind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with crohnic plaque psoriasis. J Am Acad Dermatol. 2002;47:821-83.
23. nd annual Meeting of the American Academy of Dermatology. 6-11 February 2004: Washington DC.
24. Ortonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with crohnic plaque psoriasis. JEADV. 2003;17:12-6.
25. Dedrick RL, Bodary S, Garovoy MR. Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection. Expert Opin Biol Ther. 2003;3:85-95.
26. nd Annual Meeting of the American Academy of Dermatology, February 6-11, Washington, DC.
27. nd Annual Meeting of the American Academy of Dermatology, February 6-11, Washington, DC.
28. nd Annual Meeting of the American Academy of Dermatology, February 6-11, Washington, DC.
29. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol. 2003;49:98-104.
30. Feldman SR, Carey W, Goldman M, et al. Subcutaneous Efalizumab significantly improves patient reported symptoms in patients with moderate to severe plaque psoriasis. Poster presented at Summer Meeting of the American Academy of Dermatology, July 31-Aug 4, 2002; New York, NY.
31. Krueger JG, Menter A, Tyring S, et al. National Psoriasis Fundation, psoriasis score as a tool to asses efficacy of efalizumab in the treatment of moderate to severe plaque psoriasis. Poster presented at Summer Meeting of the American Academy of Dermatology, July 31-Aug 4, 2002; New York, NY.
32. Papp KA, Miller B, Lynde C, et al. Efalizumab retreatment: Final results from an open-label study. Poster presented at Meeting of the American Association of Dermatology; March 21-26, 2003; San Francisco, California.
33. th Annual Meeting of the European Society For Dermatological Research, September 9-11, 2004, Vienna, Austria.
34. Gottlieb AB, Gordon KB, Koo J, et al. Long-term efalizumab treatment maintains clinical benefit in patients with moderate to severe plaque psoriasis: Updated findings from an open-label trial. Poster presented at Summer Academy 2003 of the American Association of Dermatology Academy; July 25-29, 2003, Chicago, Illinois.
35. th Annual Conference of the Canadian Dermatology Association, June 30 July 4, Victoria, BC, Canada 2004.
36. Leonardi C, Goffe B, Sobell J, et al. Safety of efalizumab in patients with moderate to severe crohnic plaque psoriasis. Poster presented at 65 Annual Meeting of the Society for Investigative Dermatology, April 29-May 1, 2004, Providence, RI.
37. nd Annual Meeting of the American Academy of Dermatology, February 6-11, Washington, DC.
38. Lebwohl M, Walicke P, Wang X, et al. A review of the risk of infection with efalizumab therapy. Poster presented at International Psoriasis Symposium: June 18-22, 2003; New York, NY.
39. Gottlieb A, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-32.
40. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22.
41. Van de Kerkhof PC, Randazzo B, Krueger GG, Lebwohl MG, Jahreis A. Disease characteristics and the durability of treatment response in patients with psoriasis following withdrawal from etanercept after successful clinical response. JEADV. 2004;18:259.
42. Griffiths CEM, Dubertret L, Meurer M, Randazzo B. Results of worldwide phase 3 etanercept psoriasis trial utilizing a step-down regimen. JEADV. 2004;18:250.
43. Mease P, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000;356:385-90.
44. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-72.
45. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-12.
46. Wyeth Pharmaceuticals. Enbrel. Summary of products characteristics, 2005.
47. Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol. 2001;137:893-9.
48. Wallis R, Broder M, Wong Y, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261-5.
49. Elewski B. Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol. 2002;47:796-7.
50. Newland M, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbush type. Int J Dermatol. 2002;41:449-52.
51. Chaudhari U, Romano P, Mulcahy L, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis. Lancet. 2001;357:1842-7.
52. Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005;152:954-60.
53. Gach JE, Berth-Jones J. Successful treatment of recalcitrant psoriasis with a combination of infliximab and hidroxyurea. J Dermatolog Treat. 2003;14:226-8.
54. F Remicade package insert: Malvern, Pa: Centocor, Inc; 2002.
55. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151-8.
56. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-104.
57. Lim WS, Powell RJ, Johnston ID, et al. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346:623-6.
58. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled pilot trial of infliximab, a chimeric monoclonal antibody to TNF-α in patients with moderate to severe heart failure: results of the ATTALH trail. Circulation. 2003;107:3133-40.
59. ACR Hotline. FDA advisory Committee Reviews Safety of TNF Inhibitors. Atlanta (GA); American College of Rheumatology, 2001.
60. Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis. Br J Dermatol. 2005;153:486-97.